Background Human papillomaviruses (HPVs) cause genital warts and cancers in men. The natural history of HPV infection in men is largely unknown, and that information is needed to inform prevention strategies. The goal in this study was to estimate incidence and clearance of type-specifi c genital HPV infection in men, and to assess the associated factors.
Introduction
Infection with human papillomavirus (HPV) is the cause of several diff erent diseases in men and women. 1 In the USA, an estimated 32 000 cases of cancers in men and women in 2009 were attributable to HPV infection. 2 These were cancers of the cervix, vagina, vulva, penis, oral cavity, head and neck, and anal canal. Anogenital warts are the most common outcome of HPV, with 205 cases per 100 000 diagnosed every year in the USA. 3 In addition to the diseases HPV causes directly in men, the virus is readily transmitted from men to women and greatly aff ects the risk of disease in women. [4] [5] [6] [7] [8] Because male sexual behaviour aff ects rates of HPV infection and disease in female partners, an improved understanding of the infection in men is an essential component of HPV-related cancer prevention.
Substantial progress has been made in our understanding of the effi cacy of the interventions for prevention, such as vaccination to reduce HPV-related diseases in women. 9 However, little is known about HPV infection in men, with only a few small prospective studies undertaken in Europe, [10] [11] [12] Latin America, 13 and the USA. 14, 15 Therefore, the optimum strategies for prevention of HPV infection in men are not known.
Our aim in this study was to defi ne the incidence and clearance of type-specifi c HPV infection in a cohort of men who were residing in Brazil, Mexico, and the USA, and to assess infection-associated factors.
Methods

Study population
The HPV in Men (HIM) study was a continuous prospective study of the natural history of HPV infections in men in three countries. Men were eligible for participation if they were aged 18-70 years; residents of southern Florida, USA, São Paulo, Brazil, or Cuernavaca, Mexico; reported no previous diagnosis of penile or anal cancers; reported no previous diagnosis of genital or anal warts; had not participated in an HPV vaccine study; reported no previous diagnosis of HIV; reported no current penile discharge or burning during urination; were not being treated for sexually transmitted infection; had not been imprisoned or homeless during the past 6 months; had not received drug treatment during the past 6 months; had no plans to relocate in the next 4 years; and were willing to comply with ten scheduled visits every 6 months for 4 years. Men were recruited according to three age groups (18-30 years, 31-44 years, and 45-70 years) from three diff erent population sources-general population, universities, and organised health-care systems. In Brazil, men were recruited from a large clinic in São Paulo that was providing genitourinary services, including tests for HIV and sexually transmitted infections, and the general population through television, radio, and newspaper advertisements. In Mexico, men were recruited in Cuernavaca and Morelos, through a large health plan, from factories and the military. In the USA, men were mainly recruited from the University of South Florida and the general community in Tampa, FL. A full description of cohort procedures, HPV prevalence, and factors associated with prevalent infections has already been reported.
Procedures
By use of Dacron (Digene, Gaithersburg, MD, USA) swabs prewetted with saline, three separate specimens were obtained from the coronal sulcus, glans penis, penile shaft, and scrotum, and placed in 450 μL of Specimen Transport Medium, and combined into one sample before DNA extraction. All specimens were stored at -70°C until PCR analyses and genotyping were undertaken. We have previously shown the validity of these three anatomical sites in the assessment of HPV status, and high sampling reproducibility for the detection of HPV DNA by use of this method. 19 For HPV analyses, DNA was extracted with the Media Kit (QIAGen, Valencia, CA, USA) on a robotic system according to the manufacturer's instructions. DNA was stored at 4°C until use. HPV testing was undertaken by use of PCR for amplifi cation of a fragment of the L1 gene. 20 Specimens were tested for the presence of HPV by amplifi cation of 30 ng of DNA with the PGMY09/11 L1 consensus primer system. 20 HPV genotyping was done with the linear array method 21 on all samples irrespective of the HPV PCR result (Roche Molecular Diagnostics, Alameda, CA, USA). Only samples that tested positive for β globin (99% at enrolment) were judged to be adequate and included in the analysis. Before genotyping, the amplifi cation products were run on 2% agarose gels 
Statistical analysis
Sociodemographic and sexual behavioural characteristics of participants, non-participants, and the full cohort were compared by use of Fisher's exact test for categorical variables and Van der Waerden's normal score test for continuous variables. Incidence and median time to clearance were estimated for any, oncogenic, and nononcogenic HPV types, and for every specifi c HPV type. The classifi cation of any HPV was defi ned as a positive test result for at least one of 37 HPV genotypes. HPV infections with single or multiple oncogenic virus types were classifi ed as oncogenic. Non-oncogenic infections were those that tested positive for only non-oncogenic HPV type(s). For estimates of any or type-specifi c HPV incidence, only participants who were free of any or a specifi c HPV type, respectively, at enrolment were included. Since multiple infections are possible within an individual, multiple positive tests were judged as a separate event. Person time for newly acquired HPV infection was estimated by use of the time from study entry to the date of the fi rst detection of HPV DNA, assuming a new infection arose at the date of detection. The calculation of the exact 95% CIs for incidence estimates was based on the number of events modelled as a Poisson variable for the total person months. 23 Cumulative risk of acquisition of a new infection was estimated for any HPV, HPV 16, oncogenic HPV, and nononcogenic HPV infections with the Kaplan-Meier method. Factors associated with these outcomes were assessed with proportional hazards regression. Backward-selection method, with a signifi cance threshold of 0·05, was used to identify variables included in the fi nal multivariable model. Candidate variables included race, education, marital status, smoking status, circumcision status, lifetime number of female partners, lifetime number of male anal-sex partners, number of female partners in the past 3 months, and number of male anal-sex partners in the past 3 months. Country (USA, Brazil, and Mexico) and age (years) were included in all models as design factors.
HPV clearance was defi ned as a participant testing HPV negative at two consecutive visits after testing positive. The probability of maintaining an HPV infection present at the fi rst visit or an incident infection acquired during the study period was assessed by use of the Kaplan-Meier method. Because multiple infections were possible per man, analyses were undertaken for individual type-specifi c HPV clearance. The robust sandwich estimator was used for the covariance matrix to account for within-subject correlations. 24 The proportional hazards assumption for the Cox models was tested 25 and although no gross violations were shown, HPV status at enrolment, country, age, and total number of female partners were not proportional over time in some of the HPV incidence or clearance models. However, because these covariates might be important factors in the epidemiology of HPV infection, they were retained in the fi nal models. Lifetime male anal-sex partners* All analyses were done with SAS (version 9.2), tests were two sided, and had a signifi cance level of 0·05.
Role of the funding source
Study sponsors had no role in the study design, data collection, or analysis. The corresponding author had full access to all data in the study, and had fi nal responsibility for the decision to submit for publication. 18-30 years, 12-month incidence proportion 0·39 (95% CI 0·34-0·45) 31-44 years, 12-month incidence proportion 0·41 (95% CI 0·34-0·48) 45-70 years, 12-month incidence proportion 0·33 (95% CI 0·22-0·48) Total 12-month incidence proportion 0·39 (95% CI 0·35-0·44)
Results
Study recruitment began in
18-30 years, 12-month incidence proportion 0·27 (95% CI 0·22-0·31) 31-44 years, 12-month incidence proportion 0·26 (95% CI 0·22-0·32) 45-70 years, 12-month incidence proportion 0·33 (95% CI 0·23-0·44) Total 12-month incidence proportion 0·27 (95% CI 0·24-0·30)
18-30 years, 12-month incidence proportion 0·29 (95% CI 0·25-0·34) 31-44 years, 12-month incidence proportion 0·32 (95% CI 0·26-0·38) 45-70 years, 12-month incidence proportion 0·29 (95% CI 0·19-0·41) Total 12-month incidence proportion 0·30 (95% CI 0·27-0·34) Mean age of participants was 32·1 years (SD 10·8). In the subcohort, the most common self-reported race was white, most men were uncircumcised, and most were non-smokers at enrolment (table 1) . 46 (15%) of 306 men who reported no female sexual partners in the past 3-6 months reported sexual intercourse with men. Oncogenic HPV types with the highest incidences per 1000 person months were 16, 51, 52, and 59 (table 2) . Non-oncogenic HPV types with the highest incidences per 1000 person months were 6, 62, 84, and CP6108 (table 2). The incidences of any, non-oncogenic, or oncogenic HPV infections did not vary with age (fi gure). Diff erences in cumulative incidences were also noted by country (webappendix pp 2-4). At 12 months, Brazil had the highest incidence of oncogenic infection (p=0·0109) and non-oncogenic (p<0·0001) infection; however, the risk of HPV 16 infection was highest in Mexico (p=0·0195; webappendix p 2).
Median time to clearance of infection of any HPV type was signifi cantly longer in men aged 18-30 years than in the other age groups (fi gure). For the oncogenic HPV types, median time to clearance was longest for HPV types 16, 35, and 51 ( 
Lifetime female sexual partners
Male anal-sex partners in past 3 months
Data are hazard ratios (95% CI). NA=not applicable. *Adjusted for country, age (continuous), lifetime number of female sexual partners, and recent number of male anal-sex partners. †Adjusted for country, age (continuous), current smoking status, years of education, and lifetime number of female sexual partners.
Table 3: Factors independently associated with infection with human papillomavirus (HPV)
See Online for webappendix HPV types was after a minimum of 12 months of nondetectable infection (data not shown).
In the multivariate analysis, acquisition of oncogenic HPV infection was signifi cantly higher with ten to 49 or at least 50 lifetime female sexual partners compared with not more than one, and with at least three male anal-sex partners versus none in the previous 3 months (table 3) . Acquisition of non-oncogenic HPV infection was significantly increased in men reporting two to nine and ten to 49 lifetime female sexual partners versus not more than one, current smokers, those with 13-15 years and more than 17 years of education compared with those with less than 12 years of education, and in men residing in Brazil versus those living in the USA (table 3) .
Men residing in Brazil and Mexico versus those living in the USA, and those reporting two to nine, ten to 49, and at least 50 lifetime female partners compared with no more than one were less likely to clear an oncogenic infection (table 4). The probability of clearing an oncogenic HPV infection increased with increasing age Male anal-sex partners in past 3 months
HPV status at baseline Negative 1·00 1·00 1·00 1·00 1·00 1·00
Data are hazard ratios (95% CI). *Adjusted for country, age (continuous), race, education, number of female partners in past 3 months, number of male anal-sex partners in the past 3 months, and HPV status at baseline. †Adjusted for country, age (continuous), education, lifetime number of female partners, and HPV status at baseline. ‡Adjusted for country, age (continuous), number of female partners in the past 3 months, and HPV status at baseline. 
Discussion
The incidence of genital HPV infection in men was high and relatively constant across age groups in Brazil, Mexico, and the USA. Acquisition of a new HPV infection was strongly associated with sexual behaviour with female and male sexual partners. Similarly, the probability of clearing an HPV infection was strongly associated with sexual behaviour. We noted no association with age and incidence of any, oncogenic, or non-oncogenic HPV types, although the probability of clearing these infections increased with age. Although HPV prevalence in men has been reported in several cross-sectional studies, 26 comprehensive sampling of the external genitalia or type-specifi c HPV incidence and clearance rates have been reported in few studies. Similar incidences to the overall HPV incidence reported in our study have been reported in studies of US students 15 and community men. 14 However, lower incidences were reported among Mexican 13 and Danish military men. 12 Because of diff erences in populations studied, age distribution, sampling protocols, follow-up intervals, and length of follow-up, a direct comparison of the studies is not possible. However, irrespective of the population studied, the results of all studies showed high rates of acquisition of HPV infection in men.
Whereas risk of HPV decreases with increasing age in women, 27, 28 men seem to have a stable risk for acquiring new HPV infections throughout their life. In a previous study of men in the USA, we noted that the incidence of HPV infection was constant over the age range 18-44 years.
14 In this study, the incidence was constant in men aged 18-70 years and residing in Brazil, Mexico, and USA. HPV infections acquired late in life, and those acquired at young ages and persisting, might aff ect the risk of disease in men and aff ect transmission to sexual partners at older ages. This fi nding might partly account for the bimodal HPV prevalence with age noted among women in certain Latin American countries. 29 Why there is a lack of an age association with HPV incidence in men is not known. In the HIM cohort, number of partners and new partners in the past 3 months was similar for the age groups, hence potentially providing continued exposure to HPV throughout life. Another possible explanation is sex diff erences in the HPV immune response. HPV infection of keratinised epithelium, such as the penile skin, might generate lower and weaker immune responses than infection of mucosal epithelium such as the cervix or anal canal. Men have a lower prevalence of antibodies to HPV than do women despite higher genital HPV DNA prevalence. 30 In men who have circulating HPV antibodies, titres are much lower than in women. Higher exposures (eg, large number of sexual partners) might be required in men to produce an immune response that confers protection against subsequent infections. If indeed men remain at high risk of acquiring new HPV infections through out their lives, then vaccination of older men might be warranted.
We here report faster clearance of oncogenic HPV infections in men with increasing age. The more rapid clearance noted in older men might be related to a higher prevalence of HPV antibodies in older men. 30 Caution should be taken in the interpretation of these results because we noted substantial variability in the clearance rates according to the HPV types in the group of viruses known to be carcinogenic, including HPV 16. Similar to what has been reported in women, the median time to clearance of HPV 16 is nearly two times longer (about 12 months) than with other oncogenic HPV types (eg, 6·3 months for HPV 18). Clearance of specifi c HPV types by age group needs to be further assessed in large studies.
Limitations need to be considered in the interpretion of the results of this epidemiological study. Because of the methods of recruitment and rigors of study participation, the cohort presented here is likely to be a select population. Therefore, the estimates of HPV incidence cannot be generalised to the men in the three countries. However, the assessment of factors associated with HPV acquisition and clearance are less prone to bias. HPV incidence might have been under estimated because we used the date of HPV detection as the date of occurrence. However, comparisons of incidence within the study population are probably less aff ected by this underestimation. HPV transmission to sexual partners was not directly studied.
The results from this study provide much needed data about the incidence and clearance of HPV infection in men; these data are essential for the development of realistic cost-eff ectiveness models for male HPV vaccination internationally.
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